The following content is a summary generated by the generative AI "Gemini" based on PDFs of timely disclosures published by companies.

The accuracy of the summary content cannot be guaranteed. Please be sure to check the original timely disclosure PDF before making any investment decisions.

2025-05-12 15:30
Financial ResultsGemini 2.0 Flash

21.7%減益、51.07億円

経営成績

あすか製薬ホールディングスの2025年3月期決算(連結)は、売上高641.39億円(前期比2.1%増)と微増収。営業利益は53.31億円(前期比18.0%減)、経常利益は51.07億円(前期比21.7%減)、親会社株主に帰属する当期純利益は51.01億円(前期比32.4%減)と減益。

  • 医薬品事業: 主力製品は堅調に推移。
    • 婦人科領域の「レルミナ」が105.31億円(前期比6.3%増)と伸長。
    • 月経困難症治療剤「ドロエチ」が75.02億円(前期比22.5...
Requires a subscription to the スタンダードプラン or higher.